Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement

Journal of the American Society of Nephrology

Volumn 25, Issue 8, 2014, Pages 1786-1798

  Locatelli, Monica ^a   Buelli, Simona ^a   Pezzotta, Anna ^a   Corna, Daniela ^a   Perico, Luca ^a   Tomasoni, Susanna ^a   Rottoli, Daniela ^a   Rizzo, Paola ^a   Conti, Debora ^a   Thurman, Joshua M ^b   Remuzzi, Giuseppe ^a,c   Zoja, Carlamaria ^a   Morigi, Marina ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTININ 4; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT INHIBITOR; INTEGRIN; INTEGRIN LINKED KINASE; LIPOPOLYSACCHARIDE; NEPHRIN; TRANSCRIPTION FACTOR SNAIL; VEROTOXIN 2; INTEGRIN-LINKED KINASE; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL CULTURE; CELL DAMAGE; CELL LOSS; CELL MOTILITY; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; CONTROLLED STUDY; DOWN REGULATION; GLOMERULUS BASEMENT MEMBRANE; HEMOLYTIC UREMIC SYNDROME; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; C57BL MOUSE; COMPLEMENT ALTERNATIVE PATHWAY; CULTURE TECHNIQUE; DISEASE MODEL; DRUG EFFECTS; GLOMERULUS; HEMOLYTIC-UREMIC SYNDROME; HUMAN; MALE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL CULTURE TECHNIQUES; COMPLEMENT C3A; COMPLEMENT PATHWAY, ALTERNATIVE; DISEASE MODELS, ANIMAL; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY GLOMERULUS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; PODOCYTES; PROTEIN-SERINE-THREONINE KINASES; SHIGA TOXIN 2; SIGNAL TRANSDUCTION;

EID: 84912520417     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013050450     Document Type: Article

References (56)

1. Tarr PI, Gordon CA, Chandler WL: Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365: 1073-1086, 2005
2. Noris M, Remuzzi G: Hemolytic uremic syndrome. J Am Soc Nephrol 16: 1035-1050, 2005
3. Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF: Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: A systematic review, meta-analysis, and meta-regression. JAMA 290: 1360-1370, 2003
4. Zoja C, Buelli S, Morigi M: Shiga toxin-associated hemolytic uremic syndrome: Pathophysiology of endothelial dysfunction. Pediatr Nephrol 25: 2231-2240, 2010
5. Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C: Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 187: 172-180, 2011
6. Monnens L,Molenaar J, Lambert PH, ProesmansW, vanMunster P: The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 13: 168-171, 1980
7. Koster FT, Boonpucknavig V, Sujaho S, Gilman RH, Rahaman MM: Renal histopathology in the hemolytic-uremic syndrome following shigellosis. Clin Nephrol 21: 126-133, 1984
8. Robson WL, Leung AK, Fick GH, McKenna AI: Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 62: 296-299, 1992
9. Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H: Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4: 1920-1924, 2009
10. StahlAL, Sartz L, KarpmanD:Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coliinduced hemolytic uremic syndrome. Blood 117: 5503-5513, 2011
11. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F: Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364: 2561-2563, 2011
12. Stahl R: Eculizumab experience in HUS. Presented at the 2011 American Society of Nephrology KidneyWeek, Philadelphia, PA, November 8-13, 2011
13. Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmüller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, Münte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, RiesW, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Schöcklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellhöner P, Wiesner M, Zeissig S, Büning J, Schiffer M, Kuehbacher T; EHEC-HUS consortium: Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104: H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345: e4565, 2012
14. Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S,Mees S, Stracke S, Nürnberger J, Gerke P,Wiesner M, Sucke B, Abu-TairM, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R; Collaborators of the DGfN STEC-HUS registry: Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27: 3807-3815, 2012
15. Loos S, Ahlenstiel T, Kranz B, Staude H, Pape L, Härtel C, Vester U, Buchtala L, Benz K, Hoppe B, Beringer O, Krause M, Müller D, Pohl M, Lemke J, Hillebrand G, Kreuzer M, König J, Wigger M, Konrad M, Haffner D, Oh J, Kemper MJ: An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: Presentation and short-term outcome in children. Clin Infect Dis 55: 753-759, 2012
16. Ruggenenti P, Remuzzi G: Thrombotic microangiopathy: E. coli O104: H4 German outbreak: a missed opportunity. Nat Rev Nephrol 8: 558-560, 2012
17. Welsh GI, Saleem MA: The podocyte cytoskeleton-key to a functioning glomerulus in health and disease. Nat Rev Nephrol 8: 14-21, 2012
18. Dai C, Stolz DB, Bastacky SI, St-Arnaud R, Wu C, Dedhar S, Liu Y: Essential role of integrin-linked kinase in podocyte biology: Bridging the integrin and slit diaphragm signaling. J Am Soc Nephrol 17: 2164-2175, 2006
19. Pavenstädt H, Kriz W, Kretzler M: Cell biology of the glomerular podocyte. Physiol Rev 83: 253-307, 2003
20. Benzing T: Signaling at the slit diaphragm. J AmSocNephrol 15: 1382-1391, 2004
21. Habib R: Pathology of the hemolytic uremic syndrome. In: Hemolytic Uremic Syndrome and Thrombotyc Thrombocytopenic Purpura, edited by Kaplan BS, Trompeter RS, Moake JL, New York, Marcel Dekker, Inc., 1992, pp 315-353
22. Striker GE, Striker LJ, D'Agati V: Renal lesions in hypertension. In: The Renal Biopsy: Volume 8 in theMajor Problems in Pathology Series, 3rd Ed., Philadelphia, W.B. Saunders, 1997, pp 258-268
23. Gonzalo A, Mampaso F, Gallego N, Bellas C, Segui J, Ortuño J: Hemolytic uremic syndrome with hypocomplementemia and deposits of IgM and C3 in the involved renal tissue. Clin Nephrol 16: 193-199, 1981
24. De Petris L, Patrick J, Christen E, Trachtman H: Urinary podocytemRNA excretion in children with D+HUS: A potential marker of long-term outcome. Ren Fail 28: 475-482, 2006
25. Taylor FB Jr, Tesh VL, DeBault L, Li A, Chang AC, Kosanke SD, Pysher TJ, Siegler RL: Characterization of the baboon responses to Shiga-like toxin: Descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 154: 1285-1299, 1999
26. MorigiM, Buelli S, Zanchi C, Longaretti L,Macconi D, Benigni A,Moioli D, Remuzzi G, Zoja C: Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 169: 1965-1975, 2006
27. Hughes AK, Stricklett PK, Schmid D, Kohan DE: Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells. Kidney Int 57: 2350-2359, 2000
28. Walport MJ: Complement. First of two parts.NEngl JMed 344: 1058-1066, 2001
29. Perry J, HoM, Viero S, Zheng K, Jacobs R, Thorner PS: The intermediate filament nestin is highly expressed in normal human podocytes and podocytes in glomerular disease. Pediatr Dev Pathol 10: 369-382, 2007
30. Zoja C, Garcia PB, Rota C, Conti S, Gagliardini E, Corna D, Zanchi C, Bigini P, Benigni A, Remuzzi G, Morigi M: Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. Am J Physiol Renal Physiol 303: F1370-F1381, 2012
31. Guan F, Villegas G, Teichman J, Mundel P, Tufro A: Autocrine VEGF-A systemin podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol 291: F422-F428, 2006
32. Kang YS, Li Y, Dai C, Kiss LP, Wu C, Liu Y: Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int 78: 363-373, 2010
33. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y: Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 20: 1997-2008, 2009
34. Dandapani SV, Sugimoto H, Matthews BD, Kolb RJ, Sinha S, Gerszten RE, Zhou J, Ingber DE, Kalluri R, Pollak MR: Alpha-actinin-4 is required for normal podocyte adhesion. J Biol Chem282: 467-477, 2007
35. Michaud JL, Chaisson KM, Parks RJ, Kennedy CR: FSGS-associated alpha-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. Kidney Int 70: 1054-1061, 2006
36. Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell LM, Giclas PC, Salmon J, Gilkeson G, Holers VM: A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 42: 87-97, 2005
37. Thurman JM, Royer PA, Ljubanovic D, Dursun B, Lenderink AM, Edelstein CL, Holers VM: Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J Am Soc Nephrol 17: 707-715, 2006
38. Bao L,Osawe I, HaasM,Quigg RJ: Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol 175: 1947-1955, 2005
39. BraunMC, Reins RY, Li TB, Hollmann TJ, Dutta R, Rick WA, Teng BB, Ke B: Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells. J Immunol 173: 4190-4196, 2004
40. Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS: Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28: 2097-2105, 2013
41. Zanchi C, Zoja C, Morigi M, Valsecchi F, Liu XY, Rottoli D, Locatelli M, Buelli S, Pezzotta A, Mapelli P, Geelen J, Remuzzi G, Hawiger J: Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. J Immunol 181: 1460-1469, 2008
42. KretzlerM, Teixeira VP, Unschuld PG, CohenCD,Wanke R, Edenhofer I, Mundel P, Schlöndorff D, Holthöfer H: Integrin-linked kinase as a candidate downstream effector in proteinuria. FASEB J 15: 1843-1845, 2001
43. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S: Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A 95: 11211-11216, 1998
44. Matsui I, Ito T, Kurihara H, Imai E, Ogihara T, Hori M: Snail, a transcriptional regulator, represses nephrin expression in glomerular epithelial cells of nephrotic rats. Lab Invest 87: 273-283, 2007
45. Guo L, Sanders PW,Woods A,Wu C: The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys. Am J Pathol 159: 1735-1742, 2001
46. Teixeira VP, Blattner SM, Li M, Anders HJ, Cohen CD, Edenhofer I, Calvaresi N, Merkle M, Rastaldi MP, Kretzler M: Functional consequences of integrin-linked kinase activation in podocyte damage. Kidney Int 67: 514-523, 2005
47. KosCH, Le TC, Sinha S, Henderson JM, KimSH, SugimotoH, Kalluri R, Gerszten RE, Pollak MR: Mice deficient in alpha-actinin-4 have severe glomerular disease. J Clin Invest 111: 1683-1690, 2003
48. Noris M, Mescia F, RemuzziG: STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8: 622-633, 2012
49. Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P: Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: A focus on eculizumab. Am J Kidney Dis 61: 289-299, 2013
50. Matsumoto M, Fukuda W, Circolo A, Goellner J, Strauss-Schoenberger J, Wang X, Fujita S, Hidvegi T, Chaplin DD, Colten HR: Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc Natl Acad Sci U S A 94: 8720-8725, 1997
51. Mark Taylor C: Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol 23: 1425-1431, 2008
52. Rutjes NW, Binnington BA, Smith CR, Maloney MD, Lingwood CA: Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int 62: 832-845, 2002
53. Benigni A, Zoja C, Tomasoni S, Campana M, Corna D, Zanchi C, Gagliardini E, Garofano E, Rottoli D, Ito T, Remuzzi G: Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol 17: 1624-1632, 2006
54. Weibel ER: Practical methods for biological morphometry. In: Stereological Methods, London, Academic Press, 1979, pp 40-116
55. Macconi D, Bonomelli M, Benigni A, Plati T, Sangalli F, Longaretti L, Conti S, Kawachi H, Hill P, Remuzzi G, Remuzzi A: Pathophysiologic implications of reduced podocyte number in a ratmodel of progressive glomerular injury. Am J Pathol 168: 42-54, 2006
56. SaleemMA,O'HareMJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P: A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13: 630-638, 2002